Healthcare Businesswomen's Association

Impactful Gender Equity Workplace Initiatives Earn Recognition for AstraZeneca and Parexel from the Healthcare Businesswomen's Association

Retrieved on: 
Wednesday, November 8, 2023

CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today recognized companies for their distinguished commitment to creating and implementing initiatives that deliver impactful outcomes designed to close the gender gap in the healthcare ecosystem. The awards were presented at the HBA Annual Conference in Chicago.

Key Points: 
  • CHICAGO, Nov. 8, 2023 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today recognized companies for their distinguished commitment to creating and implementing initiatives that deliver impactful outcomes designed to close the gender gap in the healthcare ecosystem.
  • (ACE) Award that recognizes results-oriented initiatives fostered by companies committed to ensuring that gender equity and leadership opportunities for women are part of their organizational DNA.
  • A panel of healthcare leaders selects recipients for their excellence in advancing their female talent and removing the systemic barriers preventing timely progress to parity.
  • The companies and initiatives recognized with this year's awards join an elite group of organizations committed to fostering programs that deliver impactful and measurable results for industry women.

HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS

Retrieved on: 
Wednesday, November 8, 2023

PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.

Key Points: 
  • PLYMOUTH MEETING, Pa., Nov. 8, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the appointment of Peter Anastasiou to the Company's Board of Directors.
  • Anastasiou held various leadership positions at Lundbeck, where he was critical in shaping overall corporate strategy, R&D priorities, and business development.
  • "I am energized to join Harmony's Board of Directors at this critical stage of growth for the company.
  • "Peter's CNS and business development expertise will support Harmony's growth priorities," said Harmony Biosciences Chairman Jeff Aronin.

Carol Prushan Appointed Senior Vice President, Advancement and Alumni Relations at The American College of Financial Services

Retrieved on: 
Tuesday, September 19, 2023

KING OF PRUSSIA, Pa., Sept. 19, 2023 /PRNewswire/ -- The American College of Financial Services is excited to announce Carol Prushan as Senior Vice President, Advancement and Alumni Relations. Working closely with The College's Executive Leadership team, Prushan will shape the advancement strategy of The College as the institution moves into its next 100 years.

Key Points: 
  • With deep experience in donor and constituent relations, Prushan will lead The College's fundraising, donor and volunteer relations, and alumni and community engagement
    KING OF PRUSSIA, Pa., Sept. 19, 2023 /PRNewswire/ -- The American College of Financial Services is excited to announce Carol Prushan as Senior Vice President, Advancement and Alumni Relations.
  • Working closely with The College's Executive Leadership team, Prushan will shape the advancement strategy of The College as the institution moves into its next 100 years.
  • Starting from September 18, Prushan will report directly to George Nichols III, CAP®, President and CEO of The American College of Financial Services.
  • "I look forward to working with my colleagues at The College to help solidify its future as a leader in financial services education," said Prushan.

Harbinger Health Expands Industry-Leading Executive Team

Retrieved on: 
Wednesday, September 6, 2023

CAMBRIDGE, Mass., Sept. 6, 2023 /PRNewswire/ -- Harbinger Health, a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today the appointment of Dymeka Harrison as Chief Commercial Officer (CCO), Mathew Sargent as Chief Business Officer (CBO), and Gisela Paulsen as Chief Operating Officer (COO), positioning the Company for continued growth and platform and product advancement.

Key Points: 
  • "Harbinger is laser-focused on our mission to create a new cancer screening paradigm by delivering accessible and low-cost early-stage screening tools," said Dr. Hahn.
  • Gisela Paulsen joined Harbinger as Chief Operating Officer, bringing over 25 years of expertise in the life sciences industry to the team.
  • She brings experience from executive roles at leading diagnostics companies Oncocyte Corporation, Exact Sciences (legacy Genomic Health) and Genentech/Roche across functions including commercial, program management, quality and regulatory, and other administrative functions.
  • Aside from her position at Harbinger Health, Ms. Paulsen is also Vice Chair of the Healthcare Businesswomen Association where she has led nominations, strategies and digital transformation committees.

AMR Appoints Kari L. Delahunty Chief Operating Officer

Retrieved on: 
Friday, September 1, 2023

KNOXVILLE, Tenn., Sept. 1, 2023 /PRNewswire/ -- Alliance for Multispecialty Research (AMR), a leading integrated research site organization, announced the appointment of Kari L. Delahunty as the Company's first Chief Operating Officer.

Key Points: 
  • KNOXVILLE, Tenn., Sept. 1, 2023 /PRNewswire/ -- Alliance for Multispecialty Research (AMR), a leading integrated research site organization, announced the appointment of Kari L. Delahunty as the Company's first Chief Operating Officer.
  • "In her role as COO, Kari will lead AMR's focus on scaling operating processes and technologies to support our rapid growth.
  • Delahunty has more than 20 years of life sciences leadership experience, with a focus on operations, strategy and management.
  • "I am excited to join AMR and look forward to further expanding the company's long-standing history of clinical excellence across geographies and therapeutic areas."

Neurocrine Biosciences Announces Appointment of Christine A. Poon to Board of Directors

Retrieved on: 
Tuesday, July 11, 2023

SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.

Key Points: 
  • SAN DIEGO, July 11, 2023 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it appointed Christine A. Poon, a business leader with extensive experience in the pharmaceutical industry, to its Board of Directors.
  • "Christine Poon brings a wealth of industry experience to Neurocrine's Board of Directors," said William H. Rastetter, Chairman of the Board of Neurocrine Biosciences.
  • "Her strong track record in leadership positions at some of the most established global biopharmaceutical enterprises will serve Neurocrine well."
  • She served as Vice Chairman and Member of the Board of Directors of Johnson & Johnson from 2005 until her retirement in March 2009.

Health Monitor Network® Welcomes Industry Veteran Kelli Vincent-Rodriguez to Build Partnerships with Over-the-Counter and Consumer Brands

Retrieved on: 
Tuesday, June 27, 2023

MONTVALE, N.J., June 27, 2023 /PRNewswire/ -- Pioneering healthcare communications company Health Monitor Network today announced the hiring of Kelli Vincent-Rodriguez as Senior Vice President for Over-the-Counter/Consumer Packaged Goods (OTC/CPG) clients. In this new leadership role, Kelli will report to Augie Caruso, Executive Vice President of Sales & Key Accounts, to position Health Monitor Network as a trusted partner to OTC/CPG brands as they strengthen their relationships with providers and patients.

Key Points: 
  • "There is a tremendous opportunity for OTC brands to build trusted relationships with patients and their healthcare providers through content.
  • Health Monitor Network is poised to facilitate these relationships," explained Kelli.
  • "I'm excited to bring my experience in consumer markets and pharmaceuticals together to help OTC brands build awareness and loyalty at the point of care."
  • "We've seen strong demand from OTC/CPG brands as they build true omnichannel marketing campaigns to better engage with healthcare practitioners," said David Paragamian, CEO at Health Monitor Network.

Delix Therapeutics Appoints Aaron Koenig, MD as Chief Medical Officer

Retrieved on: 
Monday, June 12, 2023

BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer. Dr. Koenig will oversee Delix's clinical development programs, team build-out, and broader development strategy as the company advances its psychoplastogen platform of novel disease-modifying therapeutics for serious psychiatric, neurological, and neurodegenerative disorders.

Key Points: 
  • BOSTON, June 12, 2023 /PRNewswire/ -- Delix Therapeutics (the "Company"), a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Aaron Koenig as Chief Medical Officer.
  • Dr. Koenig joins the company from Sage Therapeutics, where he served most recently as Vice President of Early Medical Science and helped design and oversee clinical-stage programs, including compounds targeting a range of neuropsychiatric and neurodegenerative and disorders.
  • "As Delix navigates its phase I trial for the novel compound DLX-001, Dr. Koenig's experience in early clinical development will be crucial to advancing our novel neuroplasticity-promoting therapeutics," said Delix Therapeutics Head of Research & Development Dr. Eliseo Salinas.
  • A non-hallucinogenic psychoplastogen, DLX-001 is the first of several psychoplastogens in the Delix platform to be approved for human trials.

CENTENE CORPORATION ANNOUNCES NEW CHIEF COMMUNICATIONS OFFICER

Retrieved on: 
Wednesday, May 24, 2023

ST. LOUIS, May 24, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today it has named Shannon T. Susko as its Senior Vice President and Chief Communications Officer.

Key Points: 
  • ST. LOUIS, May 24, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC), a leading healthcare enterprise committed to helping people live healthier lives, announced today it has named Shannon T. Susko as its Senior Vice President and Chief Communications Officer.
  • Ms. Susko will be responsible for Centene's communications function, leading the development and execution of all internal and external communications, overseeing corporate reputation and advancing communications strategy in support of the company's business objectives.
  • Ms. Susko is a seasoned communications professional with more than two decades of strategic, corporate and crisis communications experience.
  • "Shannon is an accomplished leader with a distinguished track record in strategic communications and a deep understanding of the healthcare and financial landscape," said Centene's Chief Executive Officer, Sarah M. London.

THE 4A'S WELCOMES SEVEN OUTSTANDING LEADERS TO ITS BOARD OF DIRECTORS

Retrieved on: 
Tuesday, May 9, 2023

Details on all of our new board members follows:

Key Points: 
  • Details on all of our new board members follows:
    Amber Guild, CEO, McCann New York, has been leading innovation-driven growth across advertising, media, publishing, and technology for over two decades.
  • Prior to McCann she led the Grey NY office, and prior to that she was president of The New York Times T Brand Studio.
  • Amber sits on the advisory councils of SATURDAY MORNING, 3% Movement, VCU Brandcenter and is a founding member of CHIEF.
  • He is an advisory member of the Marketing 50 and serves on the University of Southern California's Annenberg School of Communication's Board of Advisors.